سعر ارومالوك 2.5مجم30 قرص 2024

Aromalock 2.5 mg film-coated tablets (letrozole 2.5 mg), a non-steroidal aromatase inhibitor for hormone receptor-positive breast cancer in postmenopausal women, made by Marcyrl Pharmaceutical Industries, Egypt; pack of 30 tablets (3 strips).

• Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancerPopulation: Postmenopausal women (US label)DailyMed (U.S. National Library of Medicine)
• Extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifenPopulation: Postmenopausal women (US label)DailyMed (U.S. National Library of Medicine)
• First-line treatment of postmenopausal women with hormone receptor-positive or unknown advanced breast cancerPopulation: Postmenopausal women (US label)DailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>20%): hot flashes, arthralgia, flushing, asthenia, edema, headache, dizziness, hypercholesterolemia, increased sweating, bone pain and musculoskeletal pain.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Postmarketing reports include blurred vision, hepatitis and increased hepatic enzymes, anaphylaxis, angioedema, toxic epidermal necrolysis, erythema multiforme, carpal tunnel syndrome, trigger finger and tendon rupture/tendinitis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Pregnancy (may cause fetal harm).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to letrozole or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Bone effects: decreases in bone mineral density may occur; consider monitoring bone mineral density during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Cholesterol: increases in total serum cholesterol may occur; consider monitoring serum cholesterol.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Fatigue, dizziness and somnolence may occur; caution when driving or operating machinery.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• TamoxifenCoadministration of tamoxifen 20 mg daily reduced plasma letrozole levels by about 38% on average.DailyMed (U.S. National Library of Medicine)
• CimetidineCimetidine had no clinically significant effect on letrozole pharmacokinetics.DailyMed (U.S. National Library of Medicine)
• WarfarinLetrozole had no clinically significant effect on warfarin pharmacokinetics.DailyMed (U.S. National Library of Medicine)

• Letrozole can cause fetal harm and is contraindicated in pregnant women; postmarketing reports describe spontaneous abortions and congenital birth defects, and animal studies showed embryo-fetal toxicity and malformations.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• It is not known whether letrozole is present in human milk; advise women not to breastfeed during treatment and for at least 3 weeks after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Letrozole: Nonsteroidal competitive inhibitor of aromatase (CYP19): binds the heme of the cytochrome P450 subunit, blocking conversion of androgens to estrogens and lowering plasma estrone and estradiol without affecting adrenal corticosteroid or aldosterone synthesis (US label).